Standard BioTools (STU:FLB) Mohanram G-Score: 3 (As of Mar. 2026) — 50% Below Median

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

STU:FLB Standard BioTools Inc STU:FLB
39 GF Score
Price €0.75
GF Value €0.46
Valuation Significantly Overvalued
! 5 Warning Signs
View Full Analysis

What is Standard BioTools Mohanram G-Score?

Standard BioTools STU:FLB -6.29% 39 Mohanram G-Score is 3 as of Mar. 2026, which is 50% below its 10-year median of 6.00. GuruFocus rates STU:FLB with a GF Score™ of 39/100 and a GF Value™ of €0.46 (Significantly Overvalued). The stock has 5 warning signs investors should review.

Mohanram G-Score is a financial indicator developed by professor Partha Mohanram to help investors find the best investment opportunities in the growth stocks. Companies have higher G-score tends to generate higher return. According to his study, the best growth stocks that have a G-Score greater than 6 tend to beat the market, while those with a G-Score lower than 1 tend to have negative absolute returns.

Thus, the zones of discrimination were as such:

Good or high score = 6, 7, 8
Bad or low score = 0, 1

Standard BioTools has an G-score of 3.

The historical rank and industry rank for Standard BioTools's Mohanram G-Score or its related term are showing as below:

STU:FLB' s Mohanram G-Score Range Over the Past 10 Years
Min: 3   Med: 6   Max: 7
Current: 3

During the past 13 years, the highest Piotroski G-score of Standard BioTools was 7. The lowest was 3. And the median was 6.

Standard BioTools  (STU:FLB) Mohanram G-Score Explanation

Partha Mohanram is the John H. Watson Chair in Value Investing at Rotman and the Acting Vice-Dean of Research Strategy and Resources.

In 2000, he wrote a research paper called "Separating Winners from Losers Among Low Book-to-Market Stocks Using Financial Statement Analysis".

This paper tests whether a strategy based on financial statement analysis of low book-to-market (growth) stocks is successful in differentiating between winners and losers in terms of future stock performance. Based on the research, a strategy based on buying high G-score (6, 7 or 8) firms and shorting low G-score (0 or 1) firms consistently earns significant excess returns. Further, the results do not support a risk based explanation for the book-to-market effect as the strategy returns positive returns in all years, and firms that ex-ante appear less risky have better future returns.

To conclude, one can use a modified fundamental analysis strategy (G-score) to identify mispricing and earn substantial abnormal returns.


Standard BioTools Mohanram G-Score Related Terms


Standard BioTools Mohanram G-Score Historical Data

* Premium members only.

The historical data trend for Standard BioTools's Mohanram G-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Standard BioTools Mohanram G-Score Chart

Standard BioTools Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Mohanram G-Score
Get a 7-Day Free Trial Premium Member Only Premium Member Only 7.00 5.00 5.00 7.00 5.00

Standard BioTools Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Mohanram G-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 5.00 6.00 6.00 5.00 3.00

STU:FLB vs SENS, TMCI, SGHT: Mohanram G-Score Comparison

For the Medical Devices subindustry, Standard BioTools's Mohanram G-Score, along with its competitors' market caps and Mohanram G-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Standard BioTools Mohanram G-Score vs Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Standard BioTools's Mohanram G-Score distribution charts can be found below:

* The bar in red indicates where Standard BioTools's Mohanram G-Score falls into.


STU:FLB
39GF Score
Standard BioTools Inc STU:FLB
Mohanram G-Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Standard BioTools Mohanram G-Score Calculation

The calculation of the Mohanram G-score consists of eight criteria. Assign one point for each criterion met, then add up all the points to get the G-Score.

Profitability

Question 1. Return on Assets (ROA)

ROA % is calculated as Net Income divided by its average Total Assets over a certain period of time. It measures how well a company uses its asset to generate earnings.

Score 1 if ROA > ROA Industry Median, 0 otherwise.

Question 2. Cash ROA

Cash ROA equals to Cash Flow from Operations divided by average Total Assets. It measures how well a company uses its asset to generate cash.

Score 1 if Cash ROA > Cash ROA Industry Median, 0 otherwise.

Question 3. CFO and Net Income

Score 1 if CFO > Net Income, 0 otherwise.

Earnings Predictability

Question 4. Earnings Variability

Earnings Variability is measured as the variance of a firm's ROA in the past five years.

Score 1 if Earnings Variability < Earnings Variability Industry Median, 0 otherwise.

Question 5. Sales Growth Variability

Sales Growth Variability is measured as the 5-year variance in sales growth.

Score 1 if Sales Growth Variability < Sales Growth Variability Industry Median, 0 otherwise.

Accounting Conservatism

Question 6. Research & Development Intensity

Research & Development Intensity is calcualted by Research & Development divided by the beginning Total Assets.

Score 1 if Research & Development Intensity > Research & Development Intensity Industry Median, 0 otherwise.

Question 7. CAPEX Intensity

CAPEX Intensity is calcualted by Capital Expenditure divided by the beginning Total Assets.

Score 1 if CAPEX Intensity > CAPEX Intensity Industry Median, 0 otherwise.

Question 8. Advertising Expenditure Intensity

Advertising Expenditure Intensity is calcualted by Advertising Expenditure divided by the beginning Total Assets. Note that Advertising Expenditure is not reported as a seperate line item for many companies, thus Selling, General, & Admin. Expense is used in this calculation.

Score 1 if Advertising Expenditure Intensity > Advertising Expenditure Intensity Industry Median, 0 otherwise.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Note that all the Industry Median used for comparison in his original research, are substituted with Sector Median due to the limitation of data within certain countries.

Good or high score = 6, 7, 8
Bad or low score = 0, 1

Standard BioTools has an G-score of 3.

Frequently Asked Questions Learn more about Mohanram G-Score →
What does a Mohanram G-Score of 3 mean?
Standard BioTools (STU:FLB) has a Mohanram G-Score of 3 as of Mar. 2026. G-Score is a financial indicator developed by professor Partha Mohanram to help investors find the best investment opportunities in the growth stocks. View historical data on Standard BioTools and its competitors. This is 50% below median its historical median of 6.00. Over the past decade, Standard BioTools' Mohanram G-Score has ranged from 3.00 to 7.00.
Is Standard BioTools' Mohanram G-Score too high?
Standard BioTools' current Mohanram G-Score of 3 is 50% below median its 10-year median of 6.00. Over the past 10 years, this metric has ranged from a low of 3.00 to a high of 7.00. Overall, Standard BioTools has a GF Score™ of 39/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Standard BioTools' Mohanram G-Score compare to SENS and TMCI?
Standard BioTools' Mohanram G-Score of 3 can be compared against companies in the Medical Devices & Instruments industry. Historically, Standard BioTools' own Mohanram G-Score has ranged from 3.00 to 7.00 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Mohanram G-Score for a Medical Devices & Instruments company?
A good Mohanram G-Score depends on the Medical Devices & Instruments industry context. However, Mohanram G-Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Mohanram G-Score mean?
A high Mohanram G-Score can signal that a stock is expensive relative to its fundamentals. G-Score is a financial indicator developed by professor Partha Mohanram to help investors find the best investment opportunities in the growth stocks. View historical data on Standard BioTools and its competitors. Standard BioTools's current Mohanram G-Score is 3, which is 50% below median its own 10-year median of 6.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Standard BioTools stock overvalued right now?
Based on GuruFocus' analysis, Standard BioTools (STU:FLB) is currently considered Significantly Overvalued. The stock's GF Value™ is €0.46, compared to a current price of €0.75 — trading 62% above its estimated fair value. The current Mohanram G-Score is 3, which is 50% below median its 10-year median of 6.00. Standard BioTools' overall GF Score™ is 39/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Mohanram G-Score calculated?
Mohanram G-Score is calculated from a company's financial statements. For Standard BioTools (STU:FLB), the current Mohanram G-Score is 3 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Standard BioTools (STU:FLB) Overvalued in 2026?

Based on GuruFocus' analysis, Standard BioTools stock appears to be overvalued. The current stock price of €0.75 is trading 62% above its estimated GF Value™ of €0.46. GuruFocus considers Standard BioTools to be Significantly Overvalued.

Key valuation signals for STU:FLB:

  • Mohanram G-Score: 3 (50% below median its 10-year median of 6.00)
  • GF Value™: €0.46 vs. price of €0.75 (62% above fair value)
  • GF Score™: 39/100 with 5 warning signs

No single metric tells the full story. See the STU:FLB stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Standard BioTools Business Description

Other Exchanges LAB:USA
Address 50 Milk Street, 10th Floor, Boston, MA, USA, 02109
Standard BioTools Inc develops, manufactures, and sells technologies that help biomedical researchers in their search for developing medicines faster. Its tools provide insights into health and disease using proprietary mass cytometry and microfluidics technologies, which serve applications in proteomics and genomics, respectively. The company operates in one segment. Its technology includes: Genomics; Single-cell proteomics; Spatial proteomics. Its platforms include: Biomark X9 System, CyTOF XT system, and Hyperion XTi Imaging System. The company offers a diverse range of instrumentation, consumables, and services that generate high-quality data across early discovery, translational and clinical research. Geographically, it operates in Americas; EMEA and Asia-Pacific.
39GF Score

Get the complete analysis for STU:FLB

Mohanram G-Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€0.75
Price
€0.46
GF Value